株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

化膿レンサ球菌感染症 : パイプライン分析

Streptococcus pyogenes Infections - Pipeline Review, H2 2017

発行 Global Markets Direct 商品コード 279451
出版日 ページ情報 英文 37 Pages
即納可能
価格
本日の銀行送金レート: 1USD=111.00円で換算しております。
Back to Top
化膿レンサ球菌感染症 : パイプライン分析 Streptococcus pyogenes Infections - Pipeline Review, H2 2017
出版日: 2017年07月18日 ページ情報: 英文 37 Pages
概要

化膿レンサ球菌感染症とは、ストレプトコッカス・ピオゲネスというグラム陽性球菌によって起こる感染症であり、感染部分の激しい痛み、腫れ、発赤、発熱、めまい、呼吸困難、危険レベルへの血圧低下、弱脈、速脈などの症状があります。抗生剤の投与、健康的な生活習慣などの治療法があります。

当レポートでは、世界における化膿レンサ球菌感染症治療薬のパイプラインについて取り上げ、現在の開発パイプラインの状況や最新動向、薬剤プロファイル、主要企業および彼らが開発中の製品のレビューなどをお届けいたします。

目次

イントロダクション

  • 分析範囲

化膿レンサ球菌感染症の概要

治療薬の開発

  • 化膿レンサ球菌感染症向けパイプライン製品:概要
  • 化膿レンサ球菌感染症向けパイプライン製品:比較分析

化膿レンサ球菌感染症:開発中の治療薬:企業別

化膿レンサ球菌感染症:開発中の治療薬:大学・研究機関別

化膿レンサ球菌感染症:パイプライン製品の概況

  • 初期段階の製品

化膿レンサ球菌感染症:開発中の製品:企業別

化膿レンサ球菌感染症:開発中の製品:大学・研究機関別

化膿レンサ球菌感染症:治療薬開発に従事している企業

  • Absynth Biologics Limited
  • Aureogen Biosciences, Inc.
  • GlaxoSmithKline Plc
  • Helix BioMedix, Inc.
  • 大日本住友製薬
  • Wellstat Vaccines, LLC

化膿レンサ球菌感染症:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • BMY-28117
  • HB-1345
  • SM-295291
  • SM-369926
  • Small Molecules to Inhibit DHFR for Infectious Diseases
  • Small Molecules to Inhibit PolC for Gram-Positive Bacterial Infections
  • streptococcus serotype A vaccine
  • streptococcus polysaccharide serotype A vaccine
  • streptococcus pyogenes vaccine (30-valent)
    • 製品概要
    • 作用機序
    • R&Dの進捗

休止状態のプロジェクト

製品開発のマイルストーン

  • 注目のニュース・プレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9550IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Streptococcus pyogenes Infections - Pipeline Review, H2 2017, provides an overview of the Streptococcus pyogenes Infections (Infectious Disease) pipeline landscape.

Streptococcus pyogenes infections are caused by Streptococcus pyogenes, a spherical, Gram-positive bacterium. Symptoms include significant pain, swelling, and redness of infected area, fever, dizziness, difficulty breathing, dangerously low blood pressure, and a weak, rapid pulse. Treatment includes antibiotics and healthy lifestyle.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Streptococcus pyogenes Infections - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Streptococcus pyogenes Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Streptococcus pyogenes Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Streptococcus pyogenes Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 1, 4 and 3 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.

Streptococcus pyogenes Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Streptococcus pyogenes Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Streptococcus pyogenes Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Streptococcus pyogenes Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Streptococcus pyogenes Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Streptococcus pyogenes Infections (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Streptococcus pyogenes Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Streptococcus pyogenes Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Streptococcus pyogenes Infections - Overview
    • Streptococcus pyogenes Infections - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Streptococcus pyogenes Infections - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Streptococcus pyogenes Infections - Companies Involved in Therapeutics Development
    • Absynth Biologics Ltd
    • Antibiotx ApS
    • AstraZeneca Plc
    • Crestone Inc
    • Emergent BioSolutions Inc
    • Griffith University
    • Helix BioMedix Inc
    • Wellstat Vaccines LLC
  • Streptococcus pyogenes Infections - Drug Profiles
    • AZ-6142 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EV-035 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HB-1345 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • niclosamide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit PolC for Gram-Positive Bacterial Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Streptococcus [serotype A] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Streptococcus pyogenes (30-valent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Streptococcus pyogenes vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Streptococcus pyogenes vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Streptococcus pyogenes vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Streptococcus pyogenes Infections - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Streptococcus pyogenes Infections, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Streptococcus pyogenes Infections - Pipeline by Absynth Biologics Ltd, H2 2017
  • Streptococcus pyogenes Infections - Pipeline by Antibiotx ApS, H2 2017
  • Streptococcus pyogenes Infections - Pipeline by AstraZeneca Plc, H2 2017
  • Streptococcus pyogenes Infections - Pipeline by Crestone Inc, H2 2017
  • Streptococcus pyogenes Infections - Pipeline by Emergent BioSolutions Inc, H2 2017
  • Streptococcus pyogenes Infections - Pipeline by Griffith University, H2 2017
  • Streptococcus pyogenes Infections - Pipeline by Helix BioMedix Inc, H2 2017
  • Streptococcus pyogenes Infections - Pipeline by Wellstat Vaccines LLC, H2 2017
  • Streptococcus pyogenes Infections - Dormant Projects, H2 2017

List of Figures

  • Number of Products under Development for Streptococcus pyogenes Infections, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top